New nausea drug could replace standard ER treatment
NCT ID NCT06740812
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study will compare two nausea medications, fosaprepitant and metoclopramide, in 212 adults who come to the emergency department with nausea or vomiting. The goal is to see which drug provides faster and more lasting relief with fewer side effects. Fosaprepitant is a newer drug that works in the brain, while metoclopramide is the current standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fosaprepitant and metoclopramide
- What this could lead to
- If fosaprepitant works better than metoclopramide, it could offer a new, affordable option for nausea relief in emergency rooms.
- What could go wrong
- This is a Phase 4 trial, but it's still early and small (212 people). The results may not apply to all patients, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAUSEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a botox shot in the gut ease Kids' chronic vomiting?
- Can a daily capsule ease bloating and boost energy?
- Simple breathing exercises after gallbladder surgery may cut pain and nausea
- Could a Steroid-Sparing cocktail tame chemo nausea?
- Plasma power: new endoscopic treatment could heal Post-Bypass ulcers faster
- Sniff your way to better rehab? aromatherapy patches tested in hospital study